Propanc Biopharma, Inc.
PPCB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $20,964 | $48,186 | $23,793 | $160 |
| - Cash | $603 | $12 | $51 | $15 |
| + Debt | $170 | $1,727 | $1,247 | $1,209 |
| Enterprise Value | $20,530 | $49,900 | $24,989 | $1,355 |
| Revenue | $0 | $30 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | $0 | $15 | -$5 | -$4 |
| % Margin | – | 50% | – | – |
| EBITDA | -$1,504 | -$3,812 | -$53,958 | -$307 |
| % Margin | – | -12,746.4% | – | – |
| Net Income | -$4,838 | -$4,071 | -$54,067 | -$430 |
| % Margin | – | -13,615.1% | – | – |
| EPS Diluted | -0.39 | -0.35 | -12.5 | -32.22 |
| % Growth | -11.4% | 97.2% | 61.2% | – |
| Operating Cash Flow | -$1,939 | -$27 | -$136 | -$6 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$1,939 | -$27 | -$136 | -$6 |